In Vivo Testing of Radiosensitizers

  • Juliana Denekamp
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 42)


Most anticancer drugs are designed to exploit the more rapid proliferation of tumour cells than of normal cells, and are cytotoxic in certain phases of the cell cycle. Nitro-imidazoles as tumour radiosensitizers are quite different since they have an equal sensitizing action on cycling and non-cycling cells, and on cells at any stage in their cell cycle. Their tumour-specific action relates to the presence of a large fraction of hypoxic cells in tumours, and not in normal tissues.


Nerve Conduction Velocity Hypoxic Cell Enhancement Ratio Sensory Peripheral Neuropathy Increase Drug Dose 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. H. Thomlinson and L. H. Gray, The histological structure of some human lung cancers and the possible implications for radiotherapy, Brit. J. Cancer, 9: 539 (1955).PubMedCrossRefGoogle Scholar
  2. 2.
    G. E. Adams and D. L. Dewey, Hydrated electrons and radiobiological sensitization, Biochem. Biophys. Res. Comm., 12: 473 (1963).PubMedCrossRefGoogle Scholar
  3. 3.
    G. E. Adams, E. D. Clarke, I. R. Flockhart, R. S. Jacobs, D. S. Sehmi, I. J. Stratford, P. Wardman, M. E. Watts, J. Parrick, R. G. Wallace and C. E. Smithen, Structure- activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency, Int. J. Radiat. Biol., 35: 133 (1979).Google Scholar
  4. 4.
    J. F. Fowler and J. Denekamp, A review of hypoxic cell radiosensitization in experimental tumors, Pharmacol. & Ther., 7: 413 (1979).CrossRefGoogle Scholar
  5. 5.
    H. F. Withers, The dose survival relationship for irradiation of epithelial cells of mouse skin, Brit. J. Radiol., 40: 187 (1967).PubMedCrossRefGoogle Scholar
  6. 6.
    J. Denekamp and B. D. Michael, Preferential sensitization of hypoxic cells to radiation in vivo, Nature New Biol., 239: 21 (1972).PubMedGoogle Scholar
  7. 7.
    J. Denekamp, B. D. Michael and S. R. Harris, Hypoxic cell radiosensitizers: comparative tests of some electron affinie compounds using epidermal cell survival in vivo, Radiat. Res., 60:119 (1976)CrossRefGoogle Scholar
  8. 8.
    S. Dische, A. J. Gray and G. D. Zanelli, Clinical testing of the radiosensitizer Ro-07-0582. II. Radiosensitization of normal and hypoxic skin, Clinical Radiol., 27: 159 (1976).CrossRefGoogle Scholar
  9. 9.
    S. A. Hill and J. F. Fowler, Radiosensitizing and cytocidal effects on hypoxic cells of Ro-07-0582, and repair of X-ray injury, in an experimental mouse tumour, Brit. J. Cancer, 35:461 (1977).PubMedCrossRefGoogle Scholar
  10. 10.
    P. W. Sheldon and S. A. Hill, Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice, Brit. J. Cancer, 35:795 (1977).PubMedCrossRefGoogle Scholar
  11. 11.
    J. Denekamp and S. R. Harris, Tests of two electron-affinie radiosensitizers in vivo using regrowth of an experimental carcinoma, Radiat. Res., 61:191 (1975).PubMedCrossRefGoogle Scholar
  12. 12.
    J. Denekamp, D. G. Hirst, F. A. Stewart and N. H. A. Terry, Is tumour radiosensitization by misonidazole a general phenomenon? Brit. J. Cancer, 41:1 (1980).Google Scholar
  13. 13.
    R. H. Thomlinson, S. Dische, A. J. Gray and L. M. Errington, Clinical testing of the radiosensitizer Ro-07-0582. III. Response of tumours, Clinical Radiol., 27: 167 (1976).CrossRefGoogle Scholar
  14. 14.
    D. V. Ash, M. J. Peckham and G. G. Steel, A quantitative study of human tumour response to radiation and misonidazole. Brit. J. Cancer, 39:503 (1979).PubMedCrossRefGoogle Scholar
  15. 15.
    J.Denekamp, J. F. Fowler and S. Dische, The proportion of hypoxic cells in a human tumor, Int. J. Radiat. Oncol. Biol. Phys., 2:1227 (1977).PubMedCrossRefGoogle Scholar
  16. 16.
    S. Dische, M. I. Saunders, P. Anderson, R. C. Urtason, K. H. Kärcher, H. D. Kogelnik, N. M. Bleehen, T. L. Phillips and T. H. Wasserman, The neurotoxicity of misonidazole. The pooling of data from five centres, Brit. J. Radiol. 51:1023 (1978).CrossRefGoogle Scholar
  17. 17.
    J. Denekamp, N. J. McNally, J. F. Fowler and M. C. Joiner, Misonidazole in fractionated radiotherapy: little and often? Brit. J. Radiol., (in press) (1980b).Google Scholar
  18. 18.
    P. Workman, Effects of pretreatment with phenobarbitone and pehotoin on the pharmacokinetics and toxicity of misonidazole, Brit. J. Cancer, 40:335 (1979).PubMedCrossRefGoogle Scholar
  19. 19.
    D. G. Hirst, B. Vojnovic, I. J. Stratford and E. L. Travis, The effect of the radiosensitizer misonidazole on motor nerve conduction velocity in the mouse, Brit. J. Cancer, 37: Suppl. Ill: 237 (1978).Google Scholar
  20. 20.
    D. G. Hirst, B. Vojnovic and B. Hobson, Changes in nerve conduction velocity in the mouse after acute and chronic administration of nitroimidazoles, Brit. J. Cancer, 39: 159 (1979).CrossRefGoogle Scholar
  21. 21.
    C. Clarke, K. B. Dawson, P. W. Sheldon, D. J. Chaplin, I. J. Stratford and G. E. Adams, A quantitative cytochemical method for assessing the neurotoxicity of misonidazole, in: “Radiation Sensitizers: Their use in the Clinical Management of Cancer”, L. W. Brady, ed., Masson Publishing Inc., New York. (1980).Google Scholar
  22. 22.
    J. M. Brown and P. Workman, Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole, Radiat. Res., 82:171 (1980).PubMedCrossRefGoogle Scholar
  23. 23.
    J. Denekamp, Testing of hypoxic cell radiosensitizers in vivo, Cancer Clinical Trials, 3: 139 (1980).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Juliana Denekamp
    • 1
  1. 1.Gray Laboratory of the Cancer Research CampaignMount Vernon HospitalNorthwood, MiddlesexEngland

Personalised recommendations